Evidence map›Paper›PMID 40791406›Full record

ArticlebioRxiv : the preprint server for biology2025

Characterization of a Novel Transmembrane Activating STING Agonist using Genetically Humanized Mice.

Nobuyo Mizuno, Jinu Abraham, Kevin Jimenez-Perez, Ian Rose, Laura Springgay, Dylan Boehm, Takeshi Ando, Daniel Streblow, Janine Ward, Shannon Miller and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Nobuyo MizunoVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Jinu AbrahamVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Kevin Jimenez-PerezVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Ian RoseVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Laura SpringgayVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Dylan BoehmVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Takeshi AndoVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Daniel StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Janine WardInimmune Corporation, Missoula, Montana, United States of America.
Shannon MillerInimmune Corporation, Missoula, Montana, United States of America.
Uddav PandeyVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Ahmad JunaidVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
David JoynerDrexel University College of Medicine, Department of Microbiology and Immunology, Philadelphia, Pennsylvania, United States of America.
Roshell MuirWake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America.
Elias K HaddadDrexel University College of Medicine, Department of Microbiology and Immunology, Philadelphia, Pennsylvania, United States of America.
David BurkhartInimmune Corporation, Missoula, Montana, United States of America.
Omer RasheedInimmune Corporation, Missoula, Montana, United States of America.
Victor R DeFilippisVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.

Funding

Mechanistic Exploration of cGAS-STING-Mediated Vaccine EnhancementR01AI143660 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI DEFILIPPIS, VICTOR ROBERT · 2019 to 2023
$3.7M
A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging VirusesR01AI177293 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI VICTOR Robert DEFILIPPIS · 2023 to 2026
$3.1M
NIAID NIH HHS HHSN272201400055CNIAID NIH HHS R01 AI143660NIAID NIH HHS R01 AI177293
6 · The paper itself

Abstract

STING is a pattern recognition receptor that activates type I interferon and proinflammatory responses in addition to unrelated molecular processes following exposure of DNA to the cytosol. Its pharmacologic stimulation enhances vaccine potency and generates effective antitumor responses but clinical trials evaluating STING agonists have not led to approval for human use. STING activation can occur through ligand engagement of either cytosolic or transmembrane protein domains, processes to which distinct cellular phenotypes are attributed. However, the only transmembrane STING agonist identified is human selective and

Identifiers

PMID40791406
PMCPMC12338696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.